Platelets adhere to artificial surfaces in the initial stage of thrombus formation, but the subsequent steps in signal transduction that lead to platelet activation by artificial surfaces are not understood. When 0.325-pm diameter beads composed of a hydrophobic polymer, polymethylmethacrylate (PMMA), were added to gel-filtered aequorin-loaded platelets suspended in media containing Ca2+, the platelets aggregated; addition of fibrinogen was not required. Platelet aggregation was preceded by an increase in cytoplasmic Ca2+ and was accompanied by phosphorylation of the 47-Kd substrate of protein kinase C (PKC), 5-hydroxytryptamine (5-HT) release, and accumulation of phosphatidic acid. All these effects were partially inhibited by apyrase and aspirin. Monoclonal antibodies (MoAbs) 7E3 and M148 and the RTIFICIAL SURFACES interact with platelets, ini-A tially causing platelet adherence and aggregation; when such foreign surfaces are placed in contact with circulating blood, this interaction is believed to lead to thrombosis and thromboembolism and to removal of platelets from the circulation.'.* Several observations have led to the suggestion that, rather than simply causing adherence of otherwise unreacting platelets, artificial surfaces may activate platelets in a manner similar to that of soluble agonists (eg, thrombin or thromboxane 4). Platelet factor 4 and P-thromboglobulin, products of the platelet a-grandes, are found in the plasma after exposure of blood to cardiopulmonary bypass or prosthetic heart and in the whole blood surrounding platelets bound to methacrylate beads in a model ~y s t e m .~ Recently, platelets taken from patients during cardiopulmonary bypass were shown convincingly to bind monoclonal antibodies (MoAbs) that recognize activation-dependent epitopes on the platelet surface: much as is observed after stimulation with epinephrine7 or other agonists.
4 and P-thromboglobulin, products of the platelet a-grandes, are found in the plasma after exposure of blood to cardiopulmonary bypass or prosthetic heart and in the whole blood surrounding platelets bound to methacrylate beads in a model ~y s t e m .~ Recently, platelets taken from patients during cardiopulmonary bypass were shown convincingly to bind monoclonal antibodies (MoAbs) that recognize activation-dependent epitopes on the platelet surface: much as is observed after stimulation with epinephrine7 or other agonists.
The mechanism by which this activation occurs is unknown, however, as is the identity of the specific site (if any) on the platelet membrane that interacts with the foreign surface and the role of the platelet receptors for adhesive proteins in the initial response to such a surface.''8 Interference with binding of fibrinogen, and perhaps other adhesive proteins such as von Willebrand factor (vWF), to the platelet receptor complex glycoprotein (GP)IIb-IIIa9 by addition of a MoAb directed against this complex prevents platelet binding to fibrinogen-coated glass beads,'' and retention of platelets in whole blood passed through a glass bead column is partially inhibited by another MoAb directed against GPIb that inhibits ristocetin-induced binding of vWF to platelets." ADP scavengers, such as creatine phosphatelcreatine kinase, and adenylate cyclase stimulants, such as prostaglandin E, (PGE,), reduces the retention of platelets by glass beads in whole blood," although aspirin appears to have no inhibitory effect on platelet adhesion.' The extent to which initial contact of the platelets to an artificial surface and subsequent release of ADP are dependent on binding of adhesive proteins to the platelet surface is not clear, however, nor is it known what synthetic peptides RGDS and fibrinogen gamma chain fragment 400-411, all of which bind to the platelet fibrinogen receptor glycoprotein Ilb-llla (GPllb-Ma) and inhibit fibrinogen binding, prevented PMMA-induced aggregation but did not inhibit the Caz+ increase. Chymotrypsin-treated platelets aggregated after addition of fibrinogen, but not PMMA. We conclude that platelets interact initially with PMMA at membrane sites other than those required for fibrinogen binding, leading to activation of membrane phospholipases and PKC, an increase in cytoplasmic Ca2+, release of 5-HT, ADP, and fibrinogen from storage granules, and to platelet aggregation.
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signal transduction pathways connect this initial contact with platelets with aggregation and release of platelet granular contents. Therefore, we wished to test the hypothesis that stimulation of washed platelets by a representative artificial surface leads to signal transduction events usually associated with occupation of a surface receptor, such as phospholipase C activity, mobilization of intracellular Ca", and phosphorylation of platelet proteins, and to determine the role of GPIIb-IIIa occupancy in generating these signals. In these experiments, we used beads composed of polymethylmethacrylate (PMMA), a hydrophobic polymer used for intraocular lens implants and other biomedical applications" and one of a series of polymers that have been shown previously to induce platelet adhesion and aggregation.'
MATERIALS AND METHODS
Aequorin was purchased from Dr John Blinks (Rochester, MN), and fura-2 was obtained from Molecular Probes, Eugene, OR. PMMA was obtained from Polysciences, Warrington, PA in the form of beads, which were diluted in saline before use. The PMMA beads used for these experiments were 0.325 km in diameter; the total dose of PMMA to which platelets were exposed is expressed as total surface area in square millimeters per 10' platelets. MoAb 7E3 was provided in pure form as the gift of Dr Barry Coller (SUNY, Stony Brook, NY) and MoAb M-148 was purified from ascites provided by Drs Roger M. Hardisty and Michael J. Powling (Hospital for Sick Children, London, UK). The synthetic tetrapeptide Arg-Gly-Asp-Ser (RGDS) and the dodecapeptide His-His-LeuGly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val (gamma chain fragment 400-411) were gifts of Drs Marek Kloczewiak and Jack Hawiger (New England Deaconess Hospital, Boston, MA).
Blood was taken from healthy donors who had not taken aspirin or other platelet-active agents for at least 7 days before donation. Platelet-rich plasma (PRP) was obtained, and the platelets were loaded with aequorin by either of our two previously described methods.l4.l5 After loading, the platelets were gel-filtered on a column of Sepharose 2B and then suspended in HEPES-Tyrode's buffer containing Ca2+ 1 mmol/L. PMMA beads were diluted (1:20, vol/vol) with HEPES-Tyrode's buffer to make a stock suspension from which aliquots were added to the platelets.
Aequorin luminescence was measured using a platelet-ionized calcium aggregometer (Chronolog, Havertown, PA) which provided simultaneous tracings of platelet aggregation and luminescence. The PMMA beads in these amounts did not change the optical density of cell-free buffer or the luminescence of such buffer with added aequorin. The luminescent signal was converted to the intracellular Caz+ concentration ([Ca'+],) with the aid of an aequorin calibration curve constructed in our laboratory.I6 Fura-2 was loaded into platelets by incubating the PRP with 2 kmol/L Fura-2AM (acetoxymethylester form), followed by gel filtration and suspension in the Ca"-containing HEPES-Tyrode's buffer.14 Fluorescence measurements were obtained using a temperaturecontrolled dual-excitation wavelength spectrofluorimeter with stirring (SPEX, Fluorolog-2, Edison, NJ). The fluorescence signals from the two excitation wavelengths (340 and 380 nm) were stored in separate memories of a SPEX Datamate microcomputer. The recorded emission wavelength was 505 nm. Autofluorescence and light scatter produced by the PMMA beads were subtracted from each tracing. Fura-2 signals are reported as a fluorescence ratio of 340 nm:380 nm, which can be calibrated as described by Grynkiewicz et al."
Platelets were loaded with 3ZP-orthophosphate, and subsequent analysis of phosphoproteins was performed as previously described.I8 To measure production of 32P-labeled phosphatidic acid, platelet reactions were stopped by adding aliquots of the platelet suspension to 3.75 vol chloroform/methanol (1:2). Lipids were extracted as previously described." The lower chloroform fraction pooled from these extractions was evaporated under N, and redissolved in chloroform/methanol (1:l) to be spotted for thinlayer chromatography (TLC). Whatman LK5 linear K silica gel plates were washed with acetone and dried before spotting was performed. A TLC solvent system of chloroform methanol/water/ ammonium hydroxide (60:48:42) was used for resolution of acidic phospholipids. Resolved lipids were visualized with I,, and autoradiography was performed. The band corresponding to phosphatidic acid was scraped and eluted with methanol, and "P was measured by liquid scintillation spectroscopy.
In some experiments, washed platelets suspended in Tyrode's solution containing apyrase 10 U/mL and PGE, (1 pmol/L) were incubated with a-chymotrypsin (Sigma Chemical, St Louis, MO), at various concentrations for 1 hour at 37°C as previously described."J1 To inhibit proteolysis at the end of the incubation period, phenyl methyl sulfonyl fluoride (PMSF) 500 Fmol/L and soybean trypsin inhibitor 40 kmol/L were added to the incubation mixture. The platelets were then washed three times by centrifugation, and the platelet pellets were resuspended in Tyrode's buffer.
To monitor the effects of chymotrypsin on platelet GPs, the surfaces of washed platelets (final concentration, 1 X 109/mL) suspended in buffer (10 mmol/L EDTA, 10 mmol/L Tris-HC1,150 mmol/L NaCI, pH 7.4), were iodinated with NaIzI by the lactoperoxidase method. After iodination, platelets were washed twice and suspended in calcium-free HEPES-Tyrode buffer (final concentration 3 x 1OB/mL). The platelets were then treated with chymotrypsin, as described above. After incubation, platelets were lysed with Laemmli buffer [62.5 mmol/L Tris-HC1, 3% sodium dodecyl sulfate (SDS), 7% glycerol, pH 6.81. Reduced or nonreduced samples were applied to 12.5% SDS gels and subjected to electrophoresis. The radioactivity of '*'I in each polypeptide was detected by autoradiography on Kodak X-Omat AR film. Absorbance at 633 nm of these films was determined with a laser densitometer.
Extracellular levels of fibrinogen and I4C-5-hydroxytryptamine (5-HT), released from the platelet granules, and the cytoplasmic markers LDH and 3H-adenine were determined as previously described.=,= Peak Ca2+ levels induced by PMMA in the presence of antibodies or peptides were compared by analysis of variance.
Samples of control platelets or platelets after treatment with PMMA, chymotrypsin, or both PMMA and chymotrypsin were prepared for examination by scanning (SEM) or transmission (TEM) electronmicroscopy. Samples for SEM were fixed in solution with 2.5% glutaraldehyde in phosphate-buffered saline (PBS) for 1 hour. After fixation, the cells were washed, layered onto coverslips coated with poly-L-lysine (Sigma), and gently washed with PBS. The samples were dehydrated in a graded series of alcohols and critical point dried (Ladd, Burlington, VT), and sputter-coated with gold palladium (7 nm) (Polaron, Cambridge, MA). Images were obtained with a JEOL 35CF scanning electronmicroscope.
After treatment with chymotrypsin and or PMMA, samples for TEM were prepared by centrifugation (1, OOO g) to a pellet and fixed by gentle layering of glutaraldehyde (2.5% in PBS) over the washed pellet. M e r fixation, the cells were washed in Sabatini's solution (PBS with 6.8% sucrose), postfixed with osmium tetroxide (1%) in PBS for 1 hour more, dehydrated through a graded series of alcohols, and embedded in Epon, essentially as described previo~sly.~~ Nonserial sections were cut using an MT2 microtome with a diamond knife. Sections were lifted onto 3-mm grids and counterstained with uranyl acetate (2%) and lead citrate (1%). Images were obtained with a Phillips EM 300 transmission electron microscope.
RESULTS
When added to a suspension of washed, aequonn-loaded platelets (3 x 108/mL), PMMA beads [final concentration 13 to 259 mmz (total surface area)/108 platelets] produced a dose-dependent increase in aequorin luminescence, indicating an increase of [Ca'+],, in parallel with platelet aggregation (Fig 1) and release of fibrinogen into the supernatant [total at this dosage range 6 to 18 hg/mL suspension of stimulated platelets as compared with 1.4 pg/mL in the media of control (unstimulated) platelets]. PMMA in the same dosage range also caused release of 14C-labeled 5-HT; 40% of the total platelet content of 5-HT was released 3 minutes after stimulation with PMMA, 259 "'/lo8 platelets. Pretreatment of the platelets with aspirin, apyrase, or both, reduced 5-HT release to 14%, 12%, and 4%, respectively, 3 minutes after addition of a similar concentration of PMMA.
That the beads were in physical contact with the platelet surface and, in some cases, were internalized by the platelets, was shown by SEM and TEM (Fig 2) . Limited activation typically is observed in washed platelets after fixation with glutaraldehyde, as was evidenced in these studies by the loss of the ellipsoid shape and development of pseudopodial extensions (Fig 2A) . This preparation did not cause platelet degranulation, however, and no development of the canalicular system was noted with TEM ( Fig  2B) . Examination of platelets stimulated by PMMA beads showed that the beads were closely associated with the platelet surface, as shown by SEM (Fig 2C) , and appeared to be internalized by the platelets noted with "EM ( Fig  2D) . No granules were observed in the PMMA-stimulated platelets, and most of the surface canalicular system was lost (Fig 2D) . Treatment of platelets with chymotrypsin prevented association of the PMMA beads with the platelet surface, as shown by SEM (Fig 2E) . TEM showed morphology typical of activated platelets (eg, partial loss of granules and an extensive surface canalicular system), but no PMMA beads were noted intracellularly (Fig 2F) . These changes were similar to those observed in platelets treated with chymotrypsin but not stimulated by PMMA (not shown); no aggregation was morphologically evident, and the granule release was less completez than in the PMMA-treated platelets not treated with chymotrypsin (Fig 2D) .
In no instance was there platelet aggregation or secretion after PMMA that was not accompanied by an increase in [Ca'+], indicated by aequorin. Similar concentrationdependent [Ca'+], increases were noted in fura-2-loaded platelets (Fig 3) ; lower concentrations of PMMA were required to induce an aequorin-detected Caz+ increase than that shown by fluorescent indicators, as we have previously noted with other agonists.= Addition of EGTA 3 mmol/L to chelate the available extracellular Caz+ reduced but did not eliminate the [Ca"], increase at each PMMAconcentration. The persistence of the [Ca'+], increase in the presence of EGTA suggests that at least a portion of the [Ca'+], increase caused by PMMA's interaction with platelets may reflect mobilization of intracellular [Ca'+], rather than Ca'+ influx from the outside media.
When the platelets were treated with aspirin, PMMAinduced [Ca"] , increase was moderately inhibited (Fig 4) . Addition of the ADP-scavenging enzyme apyrase inhibited the [Ca'+], increase further and almost completely prevented aggregation (Fig 4) , as did ATP (data not shown). When PGE,, a stimulant of adenylate cyclase that causes an increase in cytoplasmic levels of CAMP, was added to the platelets, both PMMA-induced aggregation and [Ca"], increase were strongly inhibited. Thus, both the Ca" increase and aggregation induced by PMMA was enhanced by release of ADP and availability of cyclooxygenase metabolites, and both could be prevented by increased CAMP.
PMMA-induced platelet activation was associated with dose-dependent rapid (within 15 seconds) phosphorylation of the 47-Kd substrate (p47) of PKC (Fig 5) . Pretreating the platelets with apyrase or aspirin partially inhibited p47 phosphorylation; however, the effect of both inhibitors together was not greater than that of aspirin alone. Thus, PKC activation induced by PMMA was strongly enhanced by ADP or thromboxane A2 but did not result entirely from these release products.
We postulated that this activation of PKC could have been derived from either direct (ie, nonreceptor-mediated) activation, such as that produced by phorbol esters, or receptor-mediated generation of diacylglycerol from precursor membrane phospholipids with subsequent activation of PKC. To distinguish between these possibilities, we measured the production of phosphatidic acid (PA) in 32P-labeled platelets (Fig 6) . PMMA (259 mm2/108 platelets) produced a time-dependent accumulation of PA, which was 50% to 75% that which occurred after thrombin 0.1 U/mL
at all timc points tcstcd (data not shown). Thc PA incrcasc notcd aftcr PMMA was only slightly inhibited by aspirin and was modcratcly rcduccd with apyrasc. Addition of both apyrasc and aspirin inhibited PA production to an cxtcnt similar to that of apyrasc alonc at IS-and 30-second timc points (14% and 19% 1' 10% and 25% for apyrasc with and without aspirin, rcspcctivcly), but induced a stronger inhibitory cffcct at 60 scconds (20% v 48%). Thus, thcsc data suggcst that PMMA-induced platclct activation causcd phorpholipasc C activation and formation of diacylglyccrol, which Icd to thc accumulation of PA, and that dcpcndcncc of thcsc cvcnts on ADP or thromboxanc A, was not grcatcr than that of PKC activation, Ca" mobilization, or platclct aggrcgat ion.
Dccausc of prcvious findings' that MoAbs dircctcd against thc GPIlb-IlIa complcx prcvcntcd rctcntion of platclcts by bead columns, wc thought it possiblc that initial intcraction of thc platclct mcmbranc with PMMA might occur at this complcx. This hypothesis was tcstcd in cxpcrimcnts using the MoAbs 7E3 and M-148 and thc synthetic pcptidcs RGDS and gamma chain fragment 400-411, all of which inhibit binding of fibrinogcn and other adhcsivc proteins to thc GPllb-llla rcccptor and prcvcnt platclct aggregation induced by ADP and thrombin."'" Addition of thcsc such sitcs must bc prcscnt for platclct aggregation to occur aftcr addition of PMMA. We further examined thc ability of surface GPs to function as thc initial sitc of PMMA attachment to platclcts in cxpcrimcnts using chymotrypsin-trcatcd platclcts. Such trcatmcnt rcmovcs scvcral GPs (including GPlh and portions of GPIIb; Fig 7) platelets, however, fibrinogen can bind to otherwise unstimulatcd chymotrypsin-trcatcd platclcts and can causc aggrcgation.'".".'' Addition of PMMA did not cause aggregation of chymotrypsin-treated platelets (Fig 8) , and as notcd previously, examination by SEM and TEM showed that the PMMA beads were not in contact with the chymotrypsintreated platelets (Fig 2) . In further experiments, platclcts were loaded with Fura-2 after chymotrypsin treatment and were stimulated with thrombin 0.5 U/mL, PMMA 259 mm2/lW platelets, or the Ca:' ionophore ionomycin 5
GPlb
GPla GPllb GPllla nmol/L to 5 pmol/L. Neither ADP, thrombin, nor PMMA induced a Ca" increase in the chymotrypsin-treated platelets; such an increase was observed aftcr addition of ionomycin. Thcsc studies demonstrate that PMMA docs not serve as a fibrinogcnlikc ligand to any of thc sitcs to which fibrinogen can bind in these platelets and suggest that PMMA binds to a surface membrane structure that is removed by chymotrypsin.
DISCUSSION
In this study, we provide evidence that thc hydrophobic polymer PMMA induces aggregation and relcasc of 5-HT from washed, gel-filtered platelets. Thcsc events arc preceded by a PMMA-induced increase in [Ca'+],, activation of PKC and production of phosphatidic acid; such production is usually interpreted as an index of phospholipase C activation with subscqucnt hydrolysis of membrane phospholipids to form second messengers, especially diacylglyccro1.'9 In addition, fibrinogen binding to the platelet surfacc is required for platelet aggregation, but not the Ca" incrcasc that follows PMMA stimulation. Thus, the pathways used by PMMA to activate platelets are similar to thosc accompanying platclct activation by common soluble platelet agonists, such as thrombin or thromboxane A?, that bind to a receptor on the platclct surface, thereby gcncrat- As is the case with platelet stimulation induced by collagen or ADP,= inhibition of platelet cyclooxygenase with aspirin has a much greater inhibitory effect on PMMAinduced aggregation than on the accompanying [Ca'+], increase; in addition, degradation of ADP with apyrase inhibits both the [Ca'+], increase and platelet aggregation induced by PMMA, suggesting an important role for ADP in PMMA-induced platelet activation. The [Ca'+], increase, formation of phosphatidic acid, and phosphorylation of p47 might not be entirely the result of ADP, because these events persist after PMMA stimulation in the presence of apyrase. Thus, a sequence of events is suggested in which PMMA binds to an area on the platelet surface that can cause phospholipase C activation and an initial submaximal increase in [Ca'+],, followed by release of ADP and thromboxane A', which powerfully enhance the [Ca'+], increase and PKC activation, events that might lead to exposure of GPIIb-IIIa receptors on the platelet surface and fibrinogen binding with subsequent aggregation of platelets.g3' Altematively, interaction of PMMA with the platelet surface might produce ADP release by generating another, as yet undefined, second messenger, which would also presumably be capable of strongly enhancing subsequent ADP effects on [Ca"], increase, protein phosphorylation, and fibrinogen binding.
Identification of a specific membrane site that initially interacts with this and other artificial surfaces would be of considerable importance, both for understanding of fundamental ligand-receptor interactions and also for the design of therapeutic agents that can control the undesirable thrombotic effects of artificial surfaces when used clinically. Previous studies have shown that coating of some artificial surfaces with very dilute plasma can enhance platelet retention by bead columns and that this enhancement can be blocked by antifibrinogen antibodie~.'~ Platelets have been suggested to adhere to these surfaces through their fibrinogen receptors! As Packham noted: an unresolved problem with this concept is that these receptors do not become available to bind fibrinogen until after the platelet has been stimulated. Furthermore, platelets without GPIIbIIIa receptors (ie, from thrombasthenic patients) were recently shown to be capable of releasing their granular contents after exposure to artificial surfaces. 35 Our present findings offer a potential solution to this dilemma. Clearly, intact GPIIb-IIIa receptors are required for fibrinogen binding and aggregation caused by PMMA, as with other agonists, as shown by the experiments in which MoAbs 7E3 and M-148 and the synthetic peptides RGDS and y-chain fragment 400-411 inhibit platelet aggregation by binding to portions of the GPIIb-IIIa receptor that are presumably required for fibrinogen binding. These receptors do not appear to be the only site of initial membrane contact with PMMA, however, because the antibodies and peptides do not significantly reduce PMMA-induced [Ca*+], mobilization. Therefore, these events must follow interaction of PMMA with another site on the platelet membrane, perhaps transiently, that then leads to the binding of fibrinogen, vWF, and possibly other adhesive proteins to the GPIIb-IIIa receptors and platelet aggregation, which may be analogous to the platelet deposition or retention reported in other studies?' Added fibrinogen, which is necessary for ADP-induced aggregation of washed platelets,% is not required for PMMA-induced aggregation. The GPIIb-IIIa binding sites on these platelets are thus presumably occupied by fibrinogen derived from the platelet a-granules, which can also be released during platelet stimulation with strong agonists such as thrombin or thromboxane A2
Alternatively, a portion of the critical binding sites on GPIIb-IIIa may be occupied by adhesive proteins other than fibrinogen, such as vWF," which may be released during platelet release and clot formati~n.",'~ In several laboratories chymotrypsin has been used to remove GPs from the surface of blood platelets; platelets treated in this fashion can bind radiolabeled fibrinogen and aggregate even in the absence of ADP, which does not itself produce full a g g r e g a t i~n .~.~' .~~ Thus, these platelets are believed to have fully expressed GPIIb-IIIa receptors on their surface, much like stimulated platelets.2a~z' In the present study, chymotrypsin-treated platelets were used to examine the possibility that PMMA might interact with GPIIb-IIIa to cause aggregation, although not at sites on the complex that are bound by the MoAbs or synthetic peptides tested. Addition of PMMA did not produce aggregation of chymotrypsin-treated platelets and thus did not mimic fibrinogen in this respect. These findings do not exclude the possibility that PMMA-induced aggregation might be mediated by an epitope of GPIIIa that is cleaved by chymotrypsin in the activation of the fibrinogen receptor. Coller suggested that an equilibrium might exist between "activated" and "nonactivated" fibrinogen receptors on the platelet surface,@ implying that high fibrinogen concentrations, such as those associated with an artificial surface, would favor expression of "activated receptors." The implications of the present study are not incompatible with this concept, provided one assumes that fibrinogen fixed to an artificial surface can transiently interact with a platelet to initiate signal transduction by sites other than those used in fibrinogen binding, followed by enhancement of fibrinogen For personal use only. on September 14, 2017. by guest www.bloodjournal.org From binding to the platelet with sustained adhesion and aggregation.
Chymotrypsin also strongly degrades GPIb (Fig 7) ; thus, the inability of chymotrypsin-treated platelets to respond to PMMA could be related to the loss of this receptor. Preliminary evidence from our laboratory (J. Kang, et al, unpublished observations) suggests that MoAbs that bind to GPIb limit both aggregation and [Ca'+], increase induced by PMMA, which is consistent with that possibility. Other preliminary experiments in which GPIb was selectively digested with Serratia marcexens protease, however, showed that signal transduction occurring after addition of PMMA and other solid agonists is augmented as compared with that in intact platelets. Thus, GPIb, as well as GPIIb-IIIa, probably participates in PMMA-induced platelet activation, but further studies will be needed to define its exact role.
An important limitation of this study is that our methods of studying signal transduction in activated platelets do not lend themselves readily to studies in whole blood. The deposition of proteins such as fibrinogen or high molecular weight kininogen on artificial surfaces, as well as adherence to leukocytes, monocytes and macrophages, might be expected to alter the ability of the platelets to respond to the surface. Platelet adherence, aggregati~n,~~"~'~ and release of granular contents5 have been measured in whole blood exposed to several model surfaces, however, including the methacrylates5; because these events are similar to those demonstrated in washed platelets in the present study, the intracellular mechanisms by which these functional events occur may also be analogous. With this limitation, our finding that PMMA-treated platelets interact with artificial surfaces at a site other than GPIIb-IIIa may have clinical significance. The MoAbs and synthetic peptides used in this study, many of which are undergoing testing in humans and animal models as potentially useful antithrombotic agents,4's4' might be expected to inhibit strongly platelet aggregation induced by contact with an artificial surface. Together with results of previous studies, our results supports the concept43 that artificial surfaces can activate platelets without permanent adhesion or aggregation. Thus, initial interaction of the platelets with these surfaces might not be impaired by these antibodies or peptides, nor would any adverse effect that might result from this interaction. Alternatively, preservation of the ability of platelets to recognize artificial surfaces, while inhibiting aggregation, might ensure a proper balance between prevention of hemorrhage and an antithrombotic effect after administration of these agents.
